CIPROBAY IV FLEXIBAG Infusion Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

ciprobay iv flexibag infusion

bayer (pty) ltd - infusion - each 5,0 ml solution contains ciprofloxacin lactate equivalent to ciprofloxacin 2,0 mg

AVELOX- moxifloxacin hydrochloride injection, solution 
AVELOX- moxifloxacin hydrochloride tablet, film coated Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

avelox- moxifloxacin hydrochloride injection, solution avelox- moxifloxacin hydrochloride tablet, film coated

schering plough corporation - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3 )] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4 )]. avelox is indicated in adult patients for the treatment of complicated skin and ski

AVELOX- moxifloxacin hydrochloride injection, solution 
AVELOX- moxifloxacin hydrochloride tablet, film coated Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

avelox- moxifloxacin hydrochloride injection, solution avelox- moxifloxacin hydrochloride tablet, film coated

bayer healthcare pharmaceuticals inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg in 250 ml - avelox is indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies (14.3)] . mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. avelox is indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible staphylococcus aureus or streptococcus pyogenes [see clinical studies (14.4)]. avelox is indicated in adult patients for the treatment of complicated skin and skin

NEOPRINIL POUR-ON 5 mg/ml pour-on solution for cattle Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

neoprinil pour-on 5 mg/ml pour-on solution for cattle

virbac s.a. - eprinomectin - pour-on solution - 5 milligram(s)/millilitre - eprinomectin - cattle - endectoparasiticides

AVELOX- moxifloxacin hydrochloride tablet, film coated Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

avelox- moxifloxacin hydrochloride tablet, film coated

physicians total care, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of avelox and other antibacterial drugs, avelox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. avelox  tablets and iv are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below [see dosage and administration (2) and use in specific populations (8.5)]. culture and susceptibility testing appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin

AVELON TABLET Lõuna-Aafrika Vabariik - inglise - South African Health Products Regulatory Authority (SAHPRA)

avelon tablet

bayer (pty) ltd û isando - tablet - see ingredients - each tablet contains

Avelox IV 400 Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

avelox iv 400

bayer new zealand limited - moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin - solution for infusion - 400 mg - active: moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - avelox tablets and solution for infusion is indicated for the treatment of the following bacterial infections caused by susceptible strains: · complicated intra-abdominal infections including polymicrobial infections such as abscesses

Avelox Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

avelox

bayer new zealand limited - moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin - film coated tablet - 400 mg - active: moxifloxacin hydrochloride 436.8mg equivalent to 400 mg moxifloxacin excipient: croscarmellose sodium hypromellose iron oxide red lactose monohydrate macrogol 4000 magnesium stearate powdered cellulose titanium dioxide - avelox tablets and solution for infusion is indicated for the treatment of the following bacterial infections caused by susceptible strains: · bronchitis (acute exacerbations of chronic bronchitis)